A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients-Reference-Cited by-同舟云学术

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

Published:2019-06-27 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Melssen Marit M.,Petroni Gina R.,Chianese-Bullock Kimberly A.,Wages Nolan A.,Grosh William W.,Varhegyi Nikole,Smolkin Mark E.,Smith Kelly T.,Galeassi Nadejda V.,Deacon Donna H.,Gaughan Elizabeth M.,Slingluff Craig L.^ORCID

Funder

National Institutes of Health

National Cancer Institute

Alice and Bill Goodwin

Commonwealth Foundation for Cancer Research

Cancer Research Institute

Rebecca Clary Harris Memorial Fellowship

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0625-x.pdf

Reference52 articles.

1. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005;175:6169–76.

2. Obeid J, Hu Y, Slingluff CL Jr. Vaccines, adjuvants, and dendritic cell activators--current status and future challenges. Semin Oncol. 2015;42:549–61.

3. Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012;18:6497–508.

4. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Hibbitts S, Grosh WW, Chianese-Bullock KA, Bissonette EA, Barnd DL, Deacon DH, Patterson JW, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol. 2004;22:4474–85.

5. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med. 2013;19:465–72.

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives;Computational and Structural Biotechnology Journal;2024-12

2. Exploring treatment options in cancer: tumor treatment strategies;Signal Transduction and Targeted Therapy;2024-07-17

3. Immunopeptides: immunomodulatory strategies and prospects for ocular immunity applications;Frontiers in Immunology;2024-07-15

4. Strategies to reprogram anti-inflammatory macrophages towards pro-inflammatory macrophages to support cancer immunotherapies;Immunology Letters;2024-06

5. Orf virus as an adjuvant enhances the immune response to a PCV2 subunit vaccine;Veterinary Microbiology;2024-06